Principal Financial Group Inc. Has $241,000 Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Principal Financial Group Inc. lessened its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 25.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 5,265 shares of the company’s stock after selling 1,798 shares during the quarter. Principal Financial Group Inc.’s holdings in Keros Therapeutics were worth $241,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Ameritas Investment Partners Inc. boosted its position in shares of Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after buying an additional 324 shares during the period. Bayesian Capital Management LP purchased a new stake in shares of Keros Therapeutics during the first quarter worth $267,000. CANADA LIFE ASSURANCE Co raised its holdings in shares of Keros Therapeutics by 117.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock worth $345,000 after acquiring an additional 2,822 shares in the last quarter. Perpetual Ltd purchased a new stake in shares of Keros Therapeutics during the first quarter worth $443,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Keros Therapeutics by 99.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,916 shares of the company’s stock worth $458,000 after acquiring an additional 3,456 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Insider Buying and Selling

In related news, Director Carl L. Gordon sold 250,000 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 22.90% of the stock is owned by insiders.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $56.98 on Monday. Keros Therapeutics, Inc. has a fifty-two week low of $27.02 and a fifty-two week high of $73.00. The business has a 50-day moving average of $48.35 and a two-hundred day moving average of $53.38. The stock has a market capitalization of $2.06 billion, a P/E ratio of -11.06 and a beta of 1.22.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The business had revenue of $0.04 million for the quarter. During the same period in the previous year, the company earned ($1.27) earnings per share. As a group, research analysts expect that Keros Therapeutics, Inc. will post -4.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Bank of America cut their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday. Truist Financial reiterated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Oppenheimer assumed coverage on Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Buy” and an average target price of $89.86.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.